Home / People / Carina Healy
Picture of Carina Healy

Carina Healy


CMS Cameron McKenna Nabarro Olswang LLP
1 West Regent Street
G2 1AP
United Kingdom
Languages English

Carina Healy is partner in our Technology team with over 20 years experience advising on commercial and IP related transactions. She specialises in lifesciences and acts for a range of biotech, speciality pharma, medical device and medical technology companies. She also has a focus on academic institutions, having worked closely with long standing clients University of Glasgow, Dundee University, and University College London for many years.

Carina regularly advises her clients on large, complex and strategically important IP and commercial arrangements, including in and out licensing, clinical trials, strategic alliances, technology development collaborations, and manufacturing, supply and distribution agreements.  She is known for being commercial and pragmatic in finding ways to help her clients and their partners achieve outcomes which are beneficial for both parties

more less

"has tremendous capacity to manage large and complex transactions, to distil the key risks, and to identify commercially sensible, pragmatic solutions"

Chambers UK

Relevant experience

  • Roslin Biomed (the “Dolly the Sheep” company) through its lifecycle and on its acquisition by Geron Corp.
  • NuCana BioMed on the in-licensing and acquisition of ProTides technology from Morvus and on its subsequent agreements for pre-clinical and clinical development of NuCana’s proprietary oncology products, including Acelarin.
  • Evexar Medical on the manufacturing and supply arrangements for its premium, single use, self-illuminated medical devices and on the supply arrangements for human tissue scaffold products
  • Consilient Health Limited on the distribution arrangements for Rewisca®.
  • Advising on the establishment and operation of the Stratified Medicine Scotland Innovation Centre, a collaborative venture between 4 universities, 4 health boards and 2 industrial partners, including drafting the consortium agreement, and negotiating agreements with suppliers of bioinformatics equipment/ next generation sequencing technology.
  • UCL Business on an investment of $20m by now MeiraGTx into Athena Vision, a spin out company established to develop gene therapy products for ocular conditions, including negotiating and advising UCLB on a complex collaboration, development and licence agreement with Meira.
  • Advising on the complex contractual, IP and revenue sharing arrangements for BloodPharma, a large multi-party research collaboration funded by Wellcome Trust, for the use of stem cells in the manufacture of red blood cells.
  • Glasgow University on many complex IP licensing arrangements over 18 years, including the licensing of vaccines to Wyeth and licensing genetically engineered seed strains to Bayer.
  • Dundee University on the arrangements for a large phase IV clinical trial conducted through the Scottish Primary Care Network for a global pharmaceutical company.
  • Yantai Jereh, a Chinese oil and gas company, on the in-licensing of various products and technologies from Plexus Plc for development and commercialisation in various Asian markets.
more less


  • 1995 - Law, Dip LP. University of Glasgow, Glasgow
  • 1994 - Law, LLB (Hons), University of Glasgow, Glasgow
  • Dual Qualified in Scots and English Law
more less


Show only
21 January 2020
Scot­land: Build­ing op­por­tun­it­ies
06 Feb 20
World First as AI-de­signed Drug Starts Clin­ic­al Tri­als 
The UK-based AI drug dis­cov­ery com­pany, Ex­scien­tia, has been hailed as reach­ing a huge mile­stone: the world’s first AI-de­signed drug to enter Phase 1 clin­ic­al tri­als. Why is this a big deal? And are...
CMS Ex­pert Guide to Dis­tri­bu­tion
03 Dec 19
La­bour pro­poses Life Sci­ences Re­volu­tion
As sum­mar­ised in our earli­er art­icle, here, Jeremy Corbyn has made rad­ic­al pro­pos­als to change the United King­dom’s life sci­ences in­dustry and pat­ent re­gime. The pro­pos­als im­pact the re­search and de­vel­op­ment...
17 Dec 18
Trans­form­ing health and so­cial care
23 May 19
Frus­trated by Brexit?
In Ca­nary Wharf (BP4) T1 Ltd v European Medi­cines Agency [2019] EWHC 335 (Ch) the High Court ruled that The European Medi­cines Agency (the “EMA”) can­not use the United King­dom’s up­com­ing exit from...
11 November 2018
Life Sci­ences sec­tor spe­cial­ists
10 May 19
Uni­versity ordered to dis­close chil­dren’s clin­ic­al tri­al data 
In The Uni­versity of Bris­tol v John Peters and The In­form­a­tion Com­mis­sion­er EA/2018/0142, the First-Tier Tribunal held that an­onymised clin­ic­al tri­al data is not ex­empt from dis­clos­ure un­der The Free­dom...
Our ehealth cap­ab­il­it­ies
20 Dec 18
Launch of Life Sci­ences Sec­tor Deal 2
The In­dus­tri­al Strategy – Life Sci­ences Sec­tor Deal 2 re­port is broken down by themes with each identi­fy­ing what pro­gress has been made by each of the sec­tor and Gov­ern­ment. A sum­mary of these themes...
Hos­pit­al­ity Mat­ters - Au­tumn 2014
Cur­rent top­ics in the hotel in­dustry
27 Sep 17
Con­tract form­a­tion: so long postal ac­cept­ance?
As part of its work on the re­form of con­tract law in Scot­land, the Scot­tish Law Com­mis­sion (the “SLC”) has launched a con­sulta­tion seek­ing views on a work­ing draft of the Con­tract (Form­a­tion) (Scot­land)...